First quarter 2024 results: SCOR starts 2024 with a strong first three-months net income of EUR 196 million
May 17, 2024 01:30 ET
|
SCOR
Press release17 May 2024 - N° 07 First quarter 2024 results SCOR starts 2024 with a strong first three-months net income of EUR 196 million Group...
QIAGEN receives FDA clearance for QIAstat-Dx respiratory syndromic testing panel for fast and accurate results
May 13, 2024 02:00 ET
|
QIAGEN N.V.
Germantown, Maryland, and Venlo, the Netherlands, May 13, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA)...
Crew Energy Announces Q1 2024 Results Highlighted by a 61% AFF Margin and a 20% Increase in Condensate Production
May 09, 2024 18:39 ET
|
Crew Energy Inc
CALGARY, Alberta, May 09, 2024 (GLOBE NEWSWIRE) -- Crew Energy Inc. (TSX: CR; OTCQB: CWEGF) ("Crew" or the "Company"), a growth-oriented natural gas weighted producer operating in the world-class...
What’s New in Mammoth Lakes and at Mammoth Mountain for Summer 2024
May 09, 2024 18:00 ET
|
Visit Mammoth
Mammoth Lakes, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Mammoth Lakes is gearing up for another beautiful summer season. As the spring runoff begins in earnest and the winter snow melts away,...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
May 09, 2024 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Volaris Reports April 2024 Traffic Results: 85% Load Factor
May 09, 2024 09:00 ET
|
Controladora Vuela Compañía de Aviación, S.A.B. de C.V.
MEXICO CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Controladora Vuela Compañía de Aviación, S.A.B. de C.V. (NYSE: VLRS and BMV: VOLAR) (“Volaris” or “the Company”), the ultra-low-cost carrier (ULCC)...
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
May 07, 2024 07:00 ET
|
Rhythm Pharmaceuticals, Inc.
-- First quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $26.0 million -- -- On track to submit sNDA to the FDA to treat pediatric patients between 2 and younger than 6...
Richemont acquires Vhernier
May 07, 2024 02:02 ET
|
Compagnie Financière Richemont SA
COMPANY ANNOUNCEMENT 7 MAY 2024 RICHEMONT ACQUIRES VHERNIER ...
Wetwall™ Waterproof Wall Panel System Introduces New Pro Plus Collection
May 06, 2024 09:02 ET
|
Wilsonart
TEMPLE, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Wetwall, a Wilsonart Company, announces the launch of its new Pro Plus Collection, designed specifically for larger-scale commercial projects....
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
May 06, 2024 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
-- Oral presentation showcased previously disclosed data that demonstrate setmelanotide achieved 3.04 mean reduction in BMI-Z score and 18.4 percent mean reduction in BMI in 12 patients ages 2-<6yo...